# US 12,180,275 B2 · Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,180,275 B2
- Document ID: US12180275B2
- Status: Granted
- Kind: B2
- Application number: 17/358,480
- Filed: 2021-06-25
- Published: 2021-10-21
- Granted: 2024-12-31
- Earliest claimed: 2017-12-05
- Assignees: Progastrine et Cancers S.À R.L.
- Applicants: Progastrine et Cancers S.À R.L.
- Inventors: Alexandre Prieur
- Web page: https://patentgrep.com/patent/US12180275B2

## CPC

- C07K 16/26: against hormones {; against hormone releasing or inhibiting factors}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2818: {against CD28 or CD152}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to combinations comprising anti-progastrin (anti-hPG) monoclonal antibodies and immune checkpoint inhibitors, as well as pharmaceutical compositions comprising said combinations. Methods of treatment of cancer using said combinations are also provided.

## Claims

### Claim 1

A combination comprising:
an anti-progastrin (anti-hPG) monoclonal antibody comprising:
a heavy chain comprising CDR-H1, CDR-H2, and CDR-H3 of amino acid sequences SEQ ID NOs 28, 29, and 30, respectively, and
a light chain comprising CDR-L1, CDR-L2, and CDR-L3 of amino acid sequences SEQ ID NOs 31, 32, and 33, respectively, and
an immune checkpoint inhibitor, wherein said immune checkpoint inhibitor is an anti-PD1 antibody.

### Claim 2 (depends on 1)

The combination of claim 1, wherein said anti-hPG antibody is selected from the group consisting of single chain antibodies, camelized antibodies, chimeric antibodies, IgA1 antibodies, IgA2 antibodies, IgD antibodies, IgE antibodies, IgG1 antibodies, IgG2 antibodies, IgG3 antibodies, IgG4 antibodies, and IgM antibodies.

### Claim 3 (depends on 1)

The combination of claim 1, wherein said anti-hPG antibody is a C-terminal anti-progastrin antibody.

### Claim 4 (depends on 1)

The combination of claim 1, wherein said anti-hPG antibody is a neutralizing antibody.

### Claim 5 (depends on 1)

The combination of claim 1, wherein said anti-hPG antibody is a humanized antibody.

### Claim 6 (depends on 1)

The combination of claim 1, wherein said anti-PD1 antibody is pembrolizumab, nivolumab, cemiplimab, or pidilizumab.

### Claim 7 (depends on 1)

A method for treating colorectal cancer, comprising administering the combination of claim 1 to a patient in need thereof.

### Claim 8 (depends on 7)

The method of claim 7, wherein said anti-hPG antibody and said immune checkpoint inhibitor are administered simultaneously, separately, or sequentially.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising the combination of claim 1, a pharmaceutical acceptable vehicle, and/or an excipient.

### Claim 10

A combination comprising:
an anti-progastrin (anti-hPG) monoclonal antibody comprising:
a heavy chain variable region of amino acid sequence selected between SEQ ID NO:69 and SEQ ID NO:71, and
a light chain variable region of amino acid sequence selected between SEQ ID NO: 70 and SEQ ID NO:72, and
an immune checkpoint inhibitor, wherein said immune checkpoint inhibitor is an anti-PD1 antibody.

### Claim 11 (depends on 10)

The combination of claim 10, wherein said anti-hPG antibody comprises:
a heavy chain variable region of amino acid sequence SEQ ID NO:71 and
a light chain variable region of amino acid sequence SEQ ID NO:72,
said antibody further comprising constant regions of the light-chain and the heavy-chain derived from a human antibody.

### Claim 12 (depends on 10)

The combination of claim 10, wherein said anti-hPG antibody is selected from the group consisting of single chain antibodies, camelized antibodies, chimeric antibodies, IgA1 antibodies, IgA2 antibodies, IgD antibodies, IgE antibodies, IgG1 antibodies, IgG2 antibodies, IgG3 antibodies, IgG4 antibodies, and IgM antibodies.

### Claim 13 (depends on 10)

The combination of claim 10, wherein said anti-hPG antibody is a humanized antibody.

### Claim 14 (depends on 10)

The combination of claim 10, wherein said anti-hPG antibody is a C-terminal anti-progastrin antibody.

### Claim 15 (depends on 10)

The combination of claim 10, wherein said anti-hPG antibody is a neutralizing antibody.

### Claim 16 (depends on 10)

The combination of claim 10, wherein said anti-PD1 antibody is pembrolizumab, nivolumab, cemiplimab, or pidilizumab.

### Claim 17 (depends on 10)

A method for treating colorectal cancer, comprising administering the combination of claim 10 to a patient in need thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein said anti-hPG antibody and said immune checkpoint inhibitor are administered simultaneously, separately, or sequentially.

### Claim 19 (depends on 10)

A pharmaceutical composition comprising the combination of claim 10, a pharmaceutical acceptable vehicle, and/or an excipient.